Outlook Therapeutics' (OTLK) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK - Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

OTLK has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday. Chardan Capital reaffirmed a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Finally, BTIG Research cut their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Outlook Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $28.07.

Outlook Therapeutics Stock Up 1.8 %

Shares of NASDAQ:OTLK traded up $0.04 during trading on Friday, hitting $2.23. 1,068,963 shares of the company were exchanged, compared to its average volume of 1,067,862. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85. The company has a market capitalization of $55.55 million, a P/E ratio of -0.25 and a beta of 0.53. The business's 50 day moving average is $2.70 and its 200-day moving average is $5.35.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its quarterly earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.06. As a group, sell-side analysts anticipate that Outlook Therapeutics will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Great Point Partners LLC grew its position in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock valued at $12,557,000 after buying an additional 221,510 shares during the period. Geode Capital Management LLC boosted its stake in Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company's stock valued at $1,826,000 after acquiring an additional 112,812 shares during the last quarter. State Street Corp grew its position in shares of Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company's stock valued at $1,242,000 after acquiring an additional 21,201 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company's stock worth $275,000 after purchasing an additional 18,287 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Outlook Therapeutics in the 2nd quarter worth approximately $303,000. 11.20% of the stock is owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.